Results 221 to 230 of about 100,300 (318)

Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study

Circulation, 2012
L. Räber, M. Magro, G. Stefanini, B. Kalesan, R. V. van Domburg, Y. Onuma, P. Wenaweser, J. Daemen, B. Meier, P. Jüni, P. Serruys, S. Windecker   +11 more
semanticscholar   +1 more source

Efficacy of Drug-Coated Balloon versus Drug-Eluting Stent for Patients with De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis. [PDF]

Med Princ Pract
Haq AU, Suhail A, Ahsan W, Maqbool H, Nawal A, Hassan H, Bungish MK, Shahid MA, Wazir HU, Yousaf H, Rehman MEU, Ahmad Cheema H, Alsubari AAAMA, Khan MA, Nadeem B, Ahmed R, Ahmad A.   +16 more
europepmc   +1 more source

Study on the potential clinical significance of subclinical stent edge effects after drug-eluting stent implantation. [PDF]

Sci Rep
Xu Y, Wang YF, Zhao MY, You W, Xu T, Meng PN, Wu XQ, Wu ZM, Kong XH, Yin DL, Zhan ME, Jia HB, Liu B, Ye F.   +13 more
europepmc   +1 more source

Predictive Ability of the SYNergy Between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery Score II for Long-term Mortality in Patients with Three-vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Treated with Second-generation Drug-eluting Stents

, 2015
Jiqiang He, Xianpeng Yu, Cheng Peng, Quan Li, Ya‐Wei Luo, Yuechun Gao, Xiaoling Zhang, Changyan Wu, Hua Zhao, Yuchen Zhang, Jinghua Liu, Shuzheng Lyu, Fang Chen   +12 more
openalex   +1 more source

Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.

European Heart Journal, 2015
G. Helft, P. Steg, C. Le Feuvre, J. Georges, D. Carrié, X. Dreyfus, A. Furber, F. Leclercq, H. Eltchaninoff, J. Falquier, P. Henry, S. Cattan, L. Sebagh, P. Michel, A. Tuambilangana, N. Hammoudi, F. Boccara, G. Cayla, H. Douard, A. Diallo, E. Berman, M. Komajda, J. Metzger, E. Vicaut   +23 more
semanticscholar   +1 more source

Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis. [PDF]

Rev Cardiovasc Med
Liu B, Li M, Liu J, Xie L, Li J, Liu Y, Niu C, Xiao D, Li J, Zhang L.   +9 more
europepmc   +1 more source

The Endovascular Therapy for In-Stent Restenosis After Fluoropolymer-Based Drug-Eluting Stent Implantation in Femoropopliteal Lesions. [PDF]

JACC Asia
Horie K, Takahara M, Iida O, Soga Y, Yamaoka T, Fujihara M, Kawasaki D, Ichihashi S, Tada N.   +8 more
europepmc   +1 more source

The Design and Feasibility of Optimal Treatment for Coronary Drug-Eluting Stent In-Stent Restenosis (OPEN-ISR)-A Prospective, Randomised, Multicentre Clinical Trial. [PDF]

J Pers Med
Kulyassa PM, Németh BT, Hizoh I, Jankó LK, Ruzsa Z, Jambrik Z, Balázs BB, Becker D, Merkely B, Édes IF.   +9 more
europepmc   +1 more source

Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.

Journal of the American College of Cardiology, 2015
G. Giustino, U. Baber, S. Sartori, R. Mehran, I. Mastoris, A. Kini, Samin K. Sharma, S. Pocock, G. Dangas   +8 more
semanticscholar   +1 more source

PERCUTANEOUS CORONARY INTERVENTION ON SAPHENOUS VEIN GRAFT IN SECOND GENERATION DRUG ELUTING STENT ERA. [PDF]

Acta Clin Croat
Čanković M, Preveden A, Ivanović V, Milovančev A, Petrović M, Kovačević M, Miljković T, Bjelobrk M, Velicki L.   +8 more
europepmc   +1 more source